Sana Biotechnology, Inc. (SANA)
NASDAQ: SANA · Real-Time Price · USD
2.830
-0.020 (-0.70%)
At close: Jun 16, 2026, 4:00 PM EDT
2.850
+0.020 (0.71%)
Pre-market: Jun 17, 2026, 8:18 AM EDT
Sana Biotechnology Employees
Sana Biotechnology had 142 employees as of December 31, 2025. The number of employees decreased by 52 or -26.80% compared to the previous year.
Employees
142
Change (1Y)
-52
Growth (1Y)
-26.80%
Revenue / Employee
n/a
Profits / Employee
-$1,704,134
Market Cap
848.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 142 | -52 | -26.80% | 142 | 0 |
| Dec 31, 2024 | 194 | -134 | -40.85% | 194 | 0 |
| Dec 31, 2023 | 328 | -93 | -22.09% | 328 | 0 |
| Dec 31, 2022 | 421 | 35 | 9.07% | 418 | 3 |
| Dec 31, 2021 | 386 | 121 | 45.66% | 383 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Phathom Pharmaceuticals | 371 |
| Kura Oncology | 260 |
| Olema Pharmaceuticals | 137 |
| Alpha Tau Medical | 121 |
| Cullinan Therapeutics | 109 |
| Janux Therapeutics | 108 |
| ORIC Pharmaceuticals | 104 |
| Theravance Biopharma | 90 |
SANA News
- 7 days ago - Sana Biotechnology Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 13 days ago - Sana Biotechnology Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 14 days ago - Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 20 days ago - Sana Biotechnology to Present at June 2026 Investor Conferences - GlobeNewsWire
- 4 weeks ago - Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility - GlobeNewsWire
- 5 weeks ago - Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy - TheFly
- 5 weeks ago - Sana Biotechnology Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs - GlobeNewsWire